Breast Cancer Version 3.2014

Gradishar, William J.; Anderson, Benjamin O.; Blair, Sarah L.; Burstein, Harold J.; Cyr, Amy; Elias, Anthony; Farrar, William B.; Forero, Andres; Giordano, Sharon H.; Goldstein, Lori J.; Hayes, Daniel F.; Hudis, Clifford A.; Isakoff, Steven J.; Ljung, Britt Marie; Marcom, P. Kelly; Mayer, Ingrid A.; McCormick, Beryl; Miller, Robert S.; Pegram, Mark D.; Pierce, Lori J.; Reed, Elizabeth; Salerno, Kilian E.; Schwartzberg, Lee S.; Smith, Mary Lou; Soliman, Hatem; Somlo, George; Ward, John H.; Wolff, Antonio C.; Zellars, Richard C.; Shead, Dorothy A.; Kumar, Rashmi

doi:10.6004/jnccn.2014.0058

Cited by 173 publications

(137 citation statements)

References 192 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Although chemotherapy and hormone treatments have improved patient survival, ineffective chemotherapy remains a clinical problem owing to the disease's significant heterogeneity with different histologic components, gene-expression profiles, and mutational patterns 15. Systemic administration of chemotherapy is conventional, but current technology does not guarantee sufficient accumulation of chemotherapeutic agents at the target tumors, whereas toxicities to other vital organs remain with systemic delivery 2, 16.…”

Section: Discussionmentioning

confidence: 99%

“…It is estimated that 235,030 patients will be diagnosed with invasive breast cancer and 40,430 will die of the disease in the United States in 2014 1. Although systemic chemotherapy is one of the main therapeutic strategies for breast cancer, there is no guarantee that sufficient concentration of chemotherapeutic agents would be delivered to the target tumor without causing toxicities to other vital organs 2. In addition, previous studies have suggested that inefficient drug deposit at the target tumors via systemic administration significantly contribute to chemoresistance in cancer 3.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiofrequency Heat-Enhanced Chemotherapy for Breast Cancer: Towards Interventional Molecular Image-Guided Chemotherapy

et al. 2014

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in women worldwide. Recent developments in minimally invasive interventional radiology techniques have significantly improved breast cancer treatment. This study aimed to develop a novel technique for the local management of breast cancers using radiofrequency heat (RFH). We performed both in vitro experiments using human breast cancer cells and in vivo validation in xenograft animal models with magnetic resonance imaging (MRI) and pathological correlation to investigate the feasibility of our approach. Four treatment groups, including (1) no treatment (control), (2) RFH-only, (3) chemo (doxorubicin)-only, and (4) combination therapy with both doxorubicin and RFH, were conducted in each experiment. In vitro combination therapy significantly decreased breast cancer cell proliferation while increased their apoptosis index compared to the other three groups. MRI demonstrated a significant tumor size reduction in animals treated with combination therapy compared to those receiving other treatments in vivo. Such result was further confirmed by pathological examination. In conclusion, our findings suggests that RFH can enhance the therapeutic efficiency of doxorubicin on breast cancers, thus establishing the basis for future development of interventional molecular image-guided local chemotherapy for breast malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radiofrequency Heat-Enhanced Chemotherapy for Breast Cancer: Towards Interventional Molecular Image-Guided Chemotherapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The NCCN guidelines for breast cancer recommend surgical sentinel lymph node biopsy for clinically negative lymph nodes and either core needle biopsy or FNA for clinically suspicious lymph nodes [11]. Imaging characteristics of abnormal lymph nodes have been described, and these include cortical thickening and loss of the fatty hilum [12].…”

Section: Discussionmentioning

confidence: 99%

“…UG core biopsy represents an alternative procedure for axillary staging of patients with breast carcinoma [9,10]. Current National Comprehensive Cancer Network (NCCN) guidelines for breast carcinoma management recommend sentinel lymph node biopsy for clinically negative lymph nodes and either FNA or core-needle biopsy for clinically suspicious lymph nodes [11]. Imaging findings that indicate abnormal lymph nodes show cortical thickening and loss of the fatty hilum [12].…”

Section: Introductionmentioning

confidence: 99%

Determinants of False-Negative Fine-Needle Aspirates of Axillary Lymph Nodes in Women with Breast Cancer: Lymph Node Size, Cortical Thickness and Hilar Fat Retention

Lj²,

Cl³

et al. 2015

Acta Cytologica

View full text Add to dashboard Cite

Objective: Ultrasound-guided fine-needle aspiration (UG-FNA) is utilized to sample axillary lymph nodes in breast cancer patients. Diagnostic sensitivity is good but few data exist regarding the causes of false-negative results. Study Design: Fifty-four UG-FNAs of sentinel lymph nodes with histologic follow-up were identified. Gross and radiographic lymph node size, the percentage replaced by carcinoma and the cortical thickness were correlated with false-negative rates. Results: Thirty-seven aspirates were negative, 5 of these being false-negative (9%). True-positive lymph nodes averaged 1.3 cm in dimension while false-negatives averaged 0.92 cm. Percentage involvement by carcinoma for true-positive FNAs averaged 69% while false-negatives averaged 25%. Cortical thickness averaged 5.6 mm in true-positive FNAs but 2.9 mm in false-negatives. Conclusion: A relationship exists between lymph node size and the likelihood of a false-negative FNA. Lymph nodes <1.2 cm have a higher incidence of false-negative results. Lymph nodes with <30% involvement demonstrated a higher percentage of false-negatives than those with >30% replacement. Sentinel lymph nodes <1 cm appear to be relatively poor candidates for UG-FNA. Lymph nodes with a cortical thickness <3.5 mm are more often associated with a false-negative result than nodes with a thicker cortex.

show abstract

“…The use of the monoclonal anti-HER2 antibody trastuzumab in combination with or after adjuvant chemotherapy in medically fit patients diagnosed with tumor/node/metastasis (TNM) stage I-III HER2+ breast cancer has been the standard of care in 2015 with regard to current clinical guidelines [4,5]. The key trials investigating the benefit of adjuvant trastuzumab (National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31, North Central Cancer Treatment Group (NCCTG) N9831, Herceptin Adjuvant (HERA), and Breast Cancer International Research Group (BCIRG) 006) reported outcomes with median follow-ups of 24-36 months [6,7,8].…”

Section: Adjuvant Treatmentmentioning

confidence: 99%

Targeted Therapy in HER2-Positive Breast Cancer

Thill

Kraft²,

Friedrich³

2016

Oncol Res Treat

View full text Add to dashboard Cite

Categorization, risk assessment, and treatment of breast cancer have been revolutionized by the original description of the human epidermal growth factor receptor 2 (HER2), first as a prognostic marker and then as a therapeutic target. The HER2-positive subtype of breast cancer represents less than approximately 20% of the incident breast cancers. Nevertheless, many lessons can be learned from the development of anti-HER2 therapies in early-stage disease. This review will comment on the key studies in both the (neo)adjuvant and metastatic settings and discusses some of the controversies that still remain today both in clinical care and as research questions.

show abstract

Breast Cancer Version 3.2014

Cited by 173 publications

References 192 publications

Radiofrequency Heat-Enhanced Chemotherapy for Breast Cancer: Towards Interventional Molecular Image-Guided Chemotherapy

Radiofrequency Heat-Enhanced Chemotherapy for Breast Cancer: Towards Interventional Molecular Image-Guided Chemotherapy

Determinants of False-Negative Fine-Needle Aspirates of Axillary Lymph Nodes in Women with Breast Cancer: Lymph Node Size, Cortical Thickness and Hilar Fat Retention

Targeted Therapy in HER2-Positive Breast Cancer

Contact Info

Product

Resources

About